2026-04-25T12:52:36Z
https://www.pub.unibl.org/oai
oai:pub.unibl.org:21494
2025-12-19T04:43:59Z
Sorafenib as first line treatment for advanced liver cancer-are expiries. Ann Oncol (2011) 23 (suppl 4): iv 57.
/unibl/author/Jelena Rožić
https://www.unibl.org/sr-lat/fis/zaposlen/3371-zdenka-gojkovic
/unibl/author/S Jungić
/unibl/author/Ivanka Rakita
/unibl/author/Ž Vranješ
/unibl/author/R Rašeta
/unibl/author/G Marić
/unibl/author/M Vještica
/unibl/author/S Mijatović
/unibl/author/Predrag Dašić
/unibl/author/M Vižin
J. Rožić, Z. Gojković, S. Jungić, I. Rakita, Ž. Vranješ, R. Rašeta, G. Marić, M. Vještica, S. Mijatović, P. Dašić, M. Vižin, Sorafenib as first line treatment for advanced liver cancer-are expiries. Ann Oncol (2011) 23 (suppl 4): iv 57., This article appears in ESMO 13th World Congres of Gastrointestinal Cancer, 22-25 june 2011., 2011.
2011
Article
text
/unibl/sci/idNaucniRad:8551
This article appears in ESMO 13th World Congres of Gastrointestinal Cancer, 22-25 june 2011.
J. Rožić, Z. Gojković, S. Jungić, I. Rakita, Ž. Vranješ, R. Rašeta, G. Marić, M. Vještica, S. Mijatović, P. Dašić, M. Vižin, Sorafenib as first line treatment for advanced liver cancer-are expiries. Ann Oncol (2011) 23 (suppl 4): iv 57., This article appears in ESMO 13th World Congres of Gastrointestinal Cancer, 22-25 june 2011., 2011